NLRP3-IN-28 is a small molecule inhibitor specifically designed to target the NLRP3 inflammasome, a critical component of the innate immune system involved in inflammatory responses. This compound is part of a broader class of inhibitors aimed at modulating the activity of NLRP3, which has been implicated in various inflammatory diseases, including autoimmune disorders and metabolic syndromes. The chemical structure of NLRP3-IN-28 allows it to interact selectively with the NLRP3 protein, thereby inhibiting its activation and subsequent inflammatory signaling pathways. This inhibition can potentially lead to reduced production of pro-inflammatory cytokines, making it a candidate for therapeutic applications in conditions characterized by excessive inflammation. Additionally, studies have indicated that NLRP3-IN-28 exhibits favorable pharmacokinetic properties, enhancing its suitability for further development in clinical settings. As research continues, the full therapeutic potential and safety profile of NLRP3-IN-28 will be elucidated, contributing to the understanding of inflammasome-related pathologies.

NLRP3-IN-28

2922814-80-8: NLRP3-IN-28 is a small molecule inhibitor specifically designed to target the NLRP3 inflammasome, a critical component of the innate immune system involved in inflammatory responses. This compound is part of a broader class of inhibitors aimed at modulating the activity of NLRP3, which has been implicated in various inflammatory diseases, including autoimmune disorders and metabolic syndromes. The chemical structure of NLRP3-IN-28 allows it to interact selectively with the NLRP3 protein, thereby inhibiting its activation and subsequent inflammatory signaling pathways. This inhibition can potentially lead to reduced production of pro-inflammatory cytokines, making it a candidate for therapeutic applications in conditions characterized by excessive inflammation. Additionally, studies have indicated that NLRP3-IN-28 exhibits favorable pharmacokinetic properties, enhancing its suitability for further development in clinical settings. As research continues, the full therapeutic potential and safety profile of NLRP3-IN-28 will be elucidated, contributing to the understanding of inflammasome-related pathologies.

<p>NLRP3-IN-28 (compound N77) serves as a potent inhibitor of NLRP3, effectively blocking Nigericin-induced pyroptosis with an EC50 of 0.07μM. Additionally, it mitigates inflammatory reactions in vivo [1].</p>

CAS 2922814-80-8

NLRP3-IN-28

NLRP3-IN-28

Ref: TM-T87019